The exchange of contents and signals between organelles is key to the execution of cellular programs for growth and homeostasis, and failure of this communication can drive disease. A form of organelle communication involves exchange of cholesterol and other lipids by specialized carriers located at physical contacts between the endoplasmic reticulum (ER) and other membranes ^[@R1]--[@R3]^. Recently, cholesterol was identified as an essential activator for the master growth regulator, mTORC1 kinase. Cholesterol promotes mTORC1 recruitment from the cytosol to the lysosomal membrane, where mTORC1 triggers downstream programs for biomass production and suppression of catabolism ^[@R4]--[@R7]^. However, the mechanisms that deliver cholesterol to the lysosomal membrane to enable mTORC1 activation are unknown. More generally, whether and how inter-organelle contacts govern cell-wide programs for growth and quality control is not understood.

Under low cholesterol, mTORC1 cannot interact with its lysosomal scaffold, the Rag GTPases, and remains inactive in the cytosol. Conversely, stimulating cells with cholesterol triggers rapid, Rag GTPase-dependent translocation of mTORC1 to the lysosomal surface and activation of its kinase function ^[@R7]^. Experiments in cells and reconstituted systems suggest that the Rag GTPases specifically sense the cholesterol content of the lysosomal limiting membrane ^[@R7]^. This cholesterol pool regulates the Rags, at least in part, via SLC38A9, a multi-pass amino acid permease also required for mTORC1 activation by amino acids ^[@R7]--[@R10]^

The cellular origins of the cholesterol pool that activates mTORC1 are unclear. Exogenous cholesterol carried by low-density lipoprotein (LDL) is trafficked to the lysosomal lumen, and from there it is exported to acceptor membranes via a mechanism that requires the putative cholesterol carrier, Niemann-Pick C1 (NPC1) ^[@R11]--[@R13]^. Genetic inactivation of NPC1 in humans leads to massive accumulation of cholesterol within the lysosome, compromising its functionality and triggering Niemann-Pick type C (NPC), a fatal metabolic and neurodegenerative disease ^[@R14]^. LDL stimulates Rag- and SLC38A9-dependent activation of mTORC1 ^[@R7]^ and, in cells lacking NPC1, mTORC1 is hyper-active and cannot be switched off by cholesterol depletion, although the mechanistic basis for this constitutive activation remain unclear.

Following its NPC1-dependent export from the lysosome, cholesterol can be detected in several acceptor compartments including ER, Golgi and plasma membrane, but whether these compartments represent separate routes or rather stations in a common export pathway is unclear ^[@R1],\ [@R3],\ [@R15],\ [@R16]^. Cholesterol can also be back-transferred from the ER to several acceptor organelles, including the lysosome, via specialized carriers that reside at membrane contacts ^[@R1],\ [@R3],\ [@R15],\ [@R16]^. At which points along these routes cholesterol is made available for mTORC1 activation is unclear ^[@R7]^.

An important class of cholesterol carriers are the oxysterol binding protein (OSBP)-related proteins (ORPs) ^[@R1]--[@R3]^. ORPs contain at their C-terminus large, hydrophobic cavities that shield cholesterol molecules from the polar cytosolic environment and can also accommodate phospholipids ^[@R17],\ [@R18]^. The founding member of this family, OSBP, localizes at contacts between the ER and *trans* Golgi, where it is thought to transfer ER-derived cholesterol to the Golgi in exchange for phosphatidylinositol 4-phosphate (PI4P) ^[@R19]--[@R21]^.

OSBP was recently proposed to function at contacts between the ER and endo-lysosomes ^[@R22],\ [@R23]^. In concert with its binding partners on the ER, VAPA/B, OSBP regulates the PI4P content of endo-lysosomes, which in turn affects their actin-dependent motility ^[@R22]^. Whether OSBP also controls cholesterol levels on the lysosomal limiting membrane, and how its transport activity across ER-lysosome contacts impacts mTORC1 activation is unknown.

Here we find that, unique among several sterol carriers associated with the lysosome, OSBP establishes a lysosomal cholesterol pool that is essential for Rag GTPase-dependent mTORC1 activation. In cells lacking NPC1, unopposed ER-to-lysosome transport by OSBP drives aberrant buildup of cholesterol on the lysosomal limiting membrane. Genetic and chemical inhibition of OSBP reverses cholesterol accumulation on the limiting membrane of NPC1-null lysosomes, suppresses aberrant mTORC1 signaling and restores defective autophagy, a major driver in the pathogenesis of NPC. Thus, ER-lysosome contacts emerge as signaling nodes that coordinately regulate mTORC1 signaling and autophagy, and their manipulation via OSBP inhibitors could be beneficial in NPC and mTORC1-driven diseases.

Results {#S1}
=======

OSBP mediates cholesterol buildup on the limiting membrane of NPC1-null lysosomes {#S2}
---------------------------------------------------------------------------------

In cells lacking NPC1, mTORC1 is constitutively active and refractory to inhibition by cholesterol-depleting agents ^[@R7]^. This result appears paradoxical, because in the absence of NPC1 cholesterol should be trapped within the lysosomal interior and unable to reach its limiting membrane ^[@R11]--[@R13]^, where mTORC1 activation occurs ^[@R7]^. A possible resolution of this paradox is that, in NPC1-null lysosomes, not only the interior but also the limiting membrane could be cholesterol-enriched, a possibility consistent with the altered trafficking pattern of NPC1-null lysosomes ^[@R24]--[@R26]^. However, due to limitations of current biochemical fractionation and cholesterol-imaging approaches, it has not been possible to univocally determine the cholesterol status of the limiting membrane of NPC1-null lysosomes. To this aim, we employed a recently established cholesterol biosensor, mCherry-tagged D4H\* (derived from the *Clostridium Perfringens* theta-toxin), which binds to membranes where cholesterol exceeds 10% molar content ^[@R27]^ ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). Recombinant D4H\*-mCherry was delivered to semi-permeabilized cells using a liquid nitrogen pulse that breached the plasma membrane but left the lysosomal membrane intact ([Fig. 1a](#F1){ref-type="fig"}), as shown by retention of LysoSensor staining ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}).

In non-permeabilized HEK-293T cells, D4H\*-mCherry solely bound to the outer leaflet of the plasma membrane, consistent with its inability to cross membrane bilayers ([Supplementary Fig. 1c](#SD1){ref-type="supplementary-material"}, top). In semi-permeabilized cells with intact NPC1 function, including human fibroblasts (HFs), mouse embryonic fibroblasts (MEFs), and HEK-293T cells, D4H\*-mCherry did not bind to the cytoplasmic leaflet of lysosomes or other endomembranes, indicating that their cholesterol content is below 10% ([Fig. 1b](#F1){ref-type="fig"} and [Supplementary Fig. 1c](#SD1){ref-type="supplementary-material"} and [1d](#SD1){ref-type="supplementary-material"}). In contrast, D4H\*-mCherry showed strong lysosomal accumulation in fibroblasts from human patients carrying a pathogenic NPC1 mutation (NPC1^mut^) ([Fig. 1b](#F1){ref-type="fig"}), in *Npc1*^−/−^ mouse-derived MEFs ([Supplementary Fig. 1d](#SD1){ref-type="supplementary-material"}) ^[@R28],\ [@R29]^, in HEK-293T cells deleted for NPC1 using CRISPR/Cas9 ^[@R7]^ ([Fig. 1c](#F1){ref-type="fig"}) and in control HFs treated with the chemical NPC1 inhibitor, U18666A ^[@R30]^ ([Supplementary Fig. 1e](#SD1){ref-type="supplementary-material"} and [1f](#SD1){ref-type="supplementary-material"}). Thus, not only the lumen but also the limiting membranes of NPC1-null lysosomes show massive cholesterol accumulation.

Because LDL-derived cholesterol cannot escape the lumen of NPC1-null lysosomes ^[@R11]--[@R13]^, we hypothesized that the peripheral cholesterol buildup revealed by D4H\*-mCherry might be transferred across inter-organelle contacts. To identify carriers that could mediate cholesterol transfer to lysosomes, we carried out proteomics-based analysis of immunopurified lysosomes ^[@R7],\ [@R31],\ [@R32]^. This analysis revealed several peptides from three ORP-family carriers: OSBP, ORP8 and ORP11 ^[@R2]^ ([Fig. 1d](#F1){ref-type="fig"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). We confirmed lysosomal association of endogenous OSBP, ORP11 and ORP8 via immunoblotting of the immunopurified lysosomal samples ([Fig. 1e](#F1){ref-type="fig"}).

Strikingly, knock down of OSBP, but not ORP11, ORP8 or ORP5 (which did not score as lysosome-associated) largely reversed D4H\*-mCherry accumulation on the lysosomal surface of NPC1-null HFs and HEK-293T cells ([Fig. 1f](#F1){ref-type="fig"}--[1h](#F1){ref-type="fig"} and [Supplementary Fig. 1g](#SD1){ref-type="supplementary-material"}). In contrast, OSBP depletion did not correct luminal cholesterol accumulation of NPC1-null lysosomes, as shown by unchanged filipin staining ([Fig. 1g](#F1){ref-type="fig"} and [Supplementary Fig. 1g](#SD1){ref-type="supplementary-material"}). We confirmed this result using the natural product OSW-1, which inhibits OSBP (along with closely related OSBP2) with nanomolar potency ^[@R20],\ [@R33]^. Treatment with OSW-1 caused the D4H\*-mCherry signal, but not the filipin signal, to disappear from lysosomes of NPC1-null HFs, MEFs and HEK-293T cells ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}--[2f](#SD1){ref-type="supplementary-material"}).

Thus, unique among the ORPs, OSBP appears to be responsible for accumulation of cholesterol on the limiting membrane but not within the lumen of NPC1-null lysosomes.

OSBP localizes to ER-lysosome contacts and controls lysosomal cholesterol levels in wild-type cells {#S3}
---------------------------------------------------------------------------------------------------

OSBP was shown to mainly reside at ER-TGN contacts ^[@R19],\ [@R34],\ [@R35]^. However, in HEK-293A cells we also detected stably expressed GFP-OSBP around LAMP2-positive lysosomes ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). GFP-OSBP also co-localized with endogenous mTOR and with the p18 subunit of the Ragulator/Lamtor complex, which anchors the Rag GTPases and mTORC1 to the lysosomal membrane ^[@R5],\ [@R36]^ ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}).

Association of OSBP with LAMP2-, mTOR- or p18-positive vesicles was abolished by deletion of its pleckstrin homology (PH) domain, which anchors OSBP to the Golgi or endolysosomal membrane by binding to PI4P ^[@R22],\ [@R37]--[@R39]^ ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"} and [3b](#SD1){ref-type="supplementary-material"}). As OSBP transfers PI4P from Golgi and endolysosomes toward the ER, it is thought to weaken its own association with these organelles ^[@R19],\ [@R20]^. Consistently, a transport-defective OSBP mutant (ΔELSK) ^[@R40]^ was more strongly clustered on LAMP2-positive structures than wild-type OSBP ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). Similarly, inhibiting OSBP with OSW-1 resulted in strong clustering of GFP-OSBP to lysosomes ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). Staining HEK-293A cells with an antibody that recognizes endogenous OSBP showed partial co-localization with LAMP2 that was enhanced by shRNA-mediated depletion of VAPA/B, as previously shown ^[@R22]^ ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}).

Next, we asked whether OSBP regulates limiting membrane cholesterol of not only NPC1-null but also wild-type lysosomes. Because mCherry-D4H\* did not bind to lysosomes with intact NPC1 function, we carried out lipidomic analysis of immunopurified lysosomes ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). Inhibiting OSBP prior to immunopurification caused a 30% reduction in cholesterol content, suggesting that a significant fraction of the lysosomal cholesterol pool is ER-derived and transferred by OSBP ([Fig. 2a](#F2){ref-type="fig"}). Whole-cell lipidomics showed that, although the total cholesterol content of OSBP-depleted cells was unchanged, a larger fraction was esterified to oleic acid than in control cells ^[@R20],\ [@R38]^ ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"} and [4c](#SD1){ref-type="supplementary-material"}). Moreover, filipin staining showed strong accumulation of cholesterol in the ER of cells treated with OSBP-targeting shRNA or with the OSBP inhibitor OSW-1 ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"} and [4e](#SD1){ref-type="supplementary-material"}).

To independently visualize OSBP-dependent sterol transport to the lysosomal limiting membrane, we pulse-chased cells with a fluorescent cholesterol analog, TopFluor-cholesterol. In DMSO-treated cells, TopFluor-cholesterol initially appeared at the plasma membrane, and began accumulating in lysosomes by 30 minutes ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"} and [5b](#SD1){ref-type="supplementary-material"}). In contrast, OSW-1 treatment delayed TopFluor-cholesterol clearance from the plasma membrane and caused it to acquire an ER-like distribution, never building up in lysosomes to a noticeable degree ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"} and [5b](#SD1){ref-type="supplementary-material"}). Although off-target inhibition of other ORPs cannot be entirely ruled out, the most likely explanation for this result is that OSBP mediates a key step in a pathway that moves cholesterol from the plasma membrane to the lysosomal limiting membrane via the ER.

OSBP is essential for mTORC1 activation by cholesterol {#S4}
------------------------------------------------------

Because lysosomal membrane cholesterol drives mTORC1 activation ^[@R7]^, we tested the requirement for OSBP in mTORC1 lysosomal recruitment and kinase activation. In HEK-293T cells, OSBP was absolutely required for cholesterol-induced translocation of mTOR to LAMP2-positive structures, whereas ORP8, ORP11 or ORP5 were completely dispensable ([Fig. 2b](#F2){ref-type="fig"}, [2c](#F2){ref-type="fig"} and [Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}). Consistent with the loss of lysosomal localization, depleting OSBP strongly blunted cholesterol-dependent mTORC1 activation, as shown by loss of phosphorylation of canonical substrates S6-kinase 1 (S6K1) and 4E-binding protein 1 (4E-BP1). In contrast, knocking down ORP8, ORP11 and ORP5 had smaller or no effect on mTORC1 kinase activity ([Fig. 2d](#F2){ref-type="fig"}).

Inhibiting OSBP activity with OSW-1 also suppressed cholesterol-induced mTORC1 lysosomal recruitment and activation in a dose-dependent manner ([Fig. 2e](#F2){ref-type="fig"} and [Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"} and [6c](#SD1){ref-type="supplementary-material"}). Even under complete media conditions, OSBP ablation strongly reduced lysosomal mTORC1 recruitment ([Supplementary Fig. 6d](#SD1){ref-type="supplementary-material"} and [6e](#SD1){ref-type="supplementary-material"}) and signaling ([Supplementary Fig. 6f](#SD1){ref-type="supplementary-material"}). In contrast, OSBP depletion affected acute mTORC1 activation by amino acids only modestly, suggesting that OSBP is not directly involved in amino acid sensing ([Supplementary Fig. 6g](#SD1){ref-type="supplementary-material"}).

OSBP depletion had no effect on the lysosomal localization of RagC and p18/Lamtor1 ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Fig. 6h](#SD1){ref-type="supplementary-material"}). Thus, OSBP loss impairs the ability of the Ragulator-Rag complex to recruit mTORC1, but not its integrity. Consistent with this interpretation, stable expression of GTP-locked RagB^Q99L^ mutant, which bypasses mTORC1 inactivation by both amino acid and cholesterol depletion ^[@R4],\ [@R6],\ [@R7]^, largely rescued the effect of OSBP depletion on lysosomal mTORC1 recruitment ([Fig. 3b](#F3){ref-type="fig"} and [3c](#F3){ref-type="fig"}) and signaling ([Fig. 3d](#F3){ref-type="fig"}). Similarly, mTORC1 signaling was resistant to OSBP depletion in cells lacking the NPRL3 component of the GATOR1 complex or the KPTN subunit of the KICSTOR complex, which inactivate the Rag GTPases under low nutrients ^[@R41]--[@R43]^ ([Fig. 3e](#F3){ref-type="fig"} and [3f](#F3){ref-type="fig"}).

Taken together, these data indicate that OSBP enables mTORC1 activation by cholesterol via a pathway that converges on the Rag GTPases.

OSBP mediates ER-to-lysosome cholesterol transfer that enables mTORC1 activation {#S5}
--------------------------------------------------------------------------------

To determine whether and how the cholesterol transport function of OSBP participates in mTORC1 regulation, we reconstituted OSBP-depleted cells with isoforms lacking key functions ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}). Disabling OSBP attachment to the lysosome (by deleting or mutating the PH domain) or to the ER (by mutating the Phenylalanines in Acidic Tract (FFAT) motif that mediates OSBP interaction with VAPA/B) or both (by expressing the ORD alone) ^[@R38]^, resulted in failure to rescue mTORC1 lysosomal recruitment ([Fig. 4a](#F4){ref-type="fig"}--[4c](#F4){ref-type="fig"} and [Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}) and activation by cholesterol ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"} and [7c](#SD1){ref-type="supplementary-material"}). Disabling the OSBP transport cycle by deleting or mutating critical residues in the ORD ^[@R17],\ [@R40]^ also abolished cholesterol-dependent mTORC1 activation ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"} and [7c](#SD1){ref-type="supplementary-material"}). Thus, mTORC1 activity requires both the membrane-anchoring and lipid-transporting functions of OSBP.

Because OSBP resides at both ER-lysosome and ER-Golgi contacts, we rigorously tested whether OSBP regulates mTORC1 through lipid transport from ER to lysosomes and not elsewhere. We reconstituted OSBP-depleted cells with OSBP isoforms in which the PH domain is replaced with organelle-specific targeting signals, while retaining attachment to the ER via VAP ([Supplementary Fig. 7d](#SD1){ref-type="supplementary-material"}). Only OSBP fused to a lysosomal targeting sequence (the 39 N-terminal amino acids of p18) ^[@R5],\ [@R44]^ rescued mTORC1 activation by cholesterol, whereas OSBP isoforms targeted to mitochondria, ER and, most crucially, Golgi failed to do so ([Fig. 4d](#F4){ref-type="fig"}). Rescue of mTORC1 signaling by lysosome-targeted OSBP required its lipid-transport activity, as it was abolished by mutations in the ORD that disrupt either cholesterol or PI4P binding ([Fig. 4e](#F4){ref-type="fig"}).

The OSBP transport cycle involves exchange of cholesterol with PI4P ^[@R20],\ [@R38]^. Consistently, OSBP depletion caused strong accumulation of PI4P on lysosomes, as shown with a genetically encoded PI4P probe, GFP-P4M ^[@R37]^ ([Fig. 5a](#F5){ref-type="fig"}). To rule out a role for lysosomal PI4P buildup in mTORC1 inhibition, we fused the catalytic domain of Sac1 phosphatase, which hydrolyzes PI4P to phosphatidylinositol, to the lysosome-anchoring sequence of p18 (lyso-Sac1) ([Fig. 5b](#F5){ref-type="fig"}) ^[@R5],\ [@R37],\ [@R44]^. In OSBP-depleted cells, lyso-Sac1 completely reversed lysosomal buildup of PI4P caused by OSBP inactivation, whereas a catalytically inactive lyso-Sac1 mutant (C389S) failed to do so ([Fig. 5c](#F5){ref-type="fig"}). However, neither the catalytically active nor the inactive lyso-Sac1 restored mTORC1 activation in OSBP-depleted cells ([Fig. 5d](#F5){ref-type="fig"}). Thus, lysosomal PI4P accumulation is unlikely to contribute to mTORC1 inhibition triggered by OSBP inactivation.

Finally, consistent with OSBP functioning at ER-lysosome contacts, shRNA-mediated depletion of VAPA/B suppressed lysosomal mTORC1 localization ([Fig. 6a](#F6){ref-type="fig"} and [6b](#F6){ref-type="fig"}) and signaling ([Fig. 6c](#F6){ref-type="fig"}). While other FFAT-containing proteins including STARD3 and ORP1L ^[@R16],\ [@R45]^ also transfer cholesterol across ER-lysosome contacts, they were completely dispensable for cholesterol-dependent mTORC1 signaling ([Fig. 6d](#F6){ref-type="fig"} and [6e](#F6){ref-type="fig"}). Moreover, depletion of STARD3 or ORP1L did not reverse lysosomal surface cholesterol accumulation in NPC1-null cells, as shown by unchanged D4H\*-mCherry staining ([Fig. 6f](#F6){ref-type="fig"} and [6g](#F6){ref-type="fig"}). Thus, OSBP and VAPs form a cholesterol-transporting system at ER-lysosome contacts that is uniquely involved in mTORC1 activation by cholesterol.

NPC1 regulates the number of ER-lysosome contacts and their sterol-transporting activity {#S6}
----------------------------------------------------------------------------------------

Our D4H\*-mCherry results strongly suggest that ER-to-lysosome cholesterol transport is elevated in NPC1-null cells. Consistently, ER-lysosome contacts appeared enlarged in NPC1-null cells. In control human fibroblasts co-expressing the lysosomal and ER markers GFP-Tmem192 and mCherry-Sec61b, respectively, physical contacts between lysosomes and ER could be readily visualized ^[@R23],\ [@R46]^ ([Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}). In NPC1^mut^ fibroblasts, the ER domains in direct contact with lysosomes appeared significantly enlarged and were more persistent than those in control cells ([Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}). Further investigation using electron microscopy (EM) showed numerous ER tubules closely apposed to the characteristically enlarged NPC1-null lysosomes, recognizable by the accumulation of undigested membranes and electron-dense material within their lumen^[@R14]^ ([Supplementary Fig. 8b](#SD1){ref-type="supplementary-material"}). Because membrane contacts cannot be univocally identified by EM, we bolstered these observations with proximity ligation assay (PLA) for VAPA and LAMP2, which yields a fluorescent signal when the two membrane markers come within 10--30 nm from each other. VAP-LAMP2 PLA confirmed that ER-lysosome contacts are significantly increased in NPC1-null versus wild-type cells ([Fig. 7a](#F7){ref-type="fig"}).

To determine the mechanistic basis for enhanced ER-to-lysosome cholesterol transport, we carried out OSBP-VAP co-immunoprecipitation experiments, and found that the OSBP-VAP interaction is stronger in NPC1-null than in wild-type cells. Interestingly, in wild-type cells the OSBP-VAP interaction is promoted by cholesterol, whereas it is constitutively high in NPC1-deleted cells ([Fig. 7b](#F7){ref-type="fig"}). Thus, cholesterol may promote its own transport to the lysosome by increasing OSBP-VAP complex formation, whereas NPC1 inhibits this process, leading to OSBP-dependent cholesterol accumulation on the limiting membranes of NPC1-null lysosomes.

OSBP inactivation corrects aberrant mTORC1 signaling and defective autophagy in NPC1-null cells {#S7}
-----------------------------------------------------------------------------------------------

We previously observed that, in NPC1-null cells, mTORC1 signaling is elevated and resistant to cholesterol-depleting agents^[@R7]^. Based on the D4H\*-mCherry data and the increased formation of OSBP-VAP complexes ([Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}--[8b](#SD1){ref-type="supplementary-material"}, [Fig. 7a](#F7){ref-type="fig"} and [7b](#F7){ref-type="fig"}), we hypothesized that constitutive mTORC1 activation may be driven by OSBP-dependent accumulation of cholesterol on the limiting membrane of NPC1-null lysosomes.

Consistent with this model, knocking down OSBP resulted in complete inactivation of mTORC1, irrespective of NPC1 status ([Fig. 7c](#F7){ref-type="fig"}). Moreover, OSBP depletion suppressed constitutive lysosomal mTORC1 localization in NPC1-deleted cells ([Fig. 7d](#F7){ref-type="fig"} and [7e](#F7){ref-type="fig"}).

A major downstream consequence of aberrant mTORC1 activation is suppression of autophagy. Indeed, as in other neurodegenerative disorders, autophagic flux is decreased in NPC and it may drive the defective cellular quality control that contributes to this disease ^[@R29],\ [@R47],\ [@R48]^. Using a cleavable, dual-color LC3 reporter ^[@R49]^ we verified that autophagic flux is reduced in *Npc1*^−/−^ compared to wild-type MEFs ([Fig. 8a](#F8){ref-type="fig"}). Notably, OSBP inhibition using OSW-1 increased autophagic flux both in *Npc1*^+/+^ and *Npc1*^−/−^ cells with potency similar to the catalytic mTOR inhibitor, Torin1 ([Fig. 8a](#F8){ref-type="fig"}).

NPC1-defective MEFs and human patient fibroblasts showed pronounced accumulation of the autophagic adaptor p62/SQSTM1, indicating disrupted autophagic degradation ^[@R50]^. OSW-1 resolved p62/SQSTM1 accumulation in a dose-dependent manner, decreasing its levels to those of control cells ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"} and [8d](#SD1){ref-type="supplementary-material"}), as did shRNA-mediated OSBP knock down ([Fig. 8c](#F8){ref-type="fig"}). OSW1-induced clearance of p62/SQSTM1 was prevented by the vacuolar H+-ATPase inhibitor, bafilomycin A1 (BafA1) ([Fig. 8b](#F8){ref-type="fig"} and [Supplementary Fig. 8e](#SD1){ref-type="supplementary-material"}). Importantly, mTORC1 inhibition via Torin1 was as effective as OSW-1 in clearing p62/SQSTM1, and their combined treatment provided no additional benefit, suggesting that both compounds act via a mechanism converging on mTORC1 ([Fig. 8b](#F8){ref-type="fig"} and [Supplementary Fig. 8f](#SD1){ref-type="supplementary-material"}).

Immunofluorescence for p62 in human patient fibroblasts showed massive accumulation of intracellular aggregates in NPC1^mut^ cells that partially overlapped with LAMP2-positive lysosomes ([Fig. 8d](#F8){ref-type="fig"} and [8e](#F8){ref-type="fig"}). Consistent with the immunoblotting results, intracellular p62/SQSTM1 aggregates were largely cleared by treatment with OSW-1 and Torin1, and this effect was reversed by BafA1 ([Fig. 8d](#F8){ref-type="fig"} and [8e](#F8){ref-type="fig"}). Together, these data demonstrate that inhibiting aberrant, OSBP-driven mTORC1 signaling in NPC cells is sufficient to restore delivery of autophagic cargo to the lysosome and its subsequent degradation.

Discussion {#S8}
==========

This work identifies OSBP as the key component of a transport circuit that coordinately regulates cholesterol levels and mTORC1 activation at the lysosomal membrane ([Fig. 8f](#F8){ref-type="fig"}). In concert with its ER membrane anchor, VAPA/B, OSBP delivers cholesterol in the ER-to-lysosome direction in exchange for PI4P ^[@R22],\ [@R38]^. Cholesterol deposited on the lysosome by OSBP may directly interact with the mTORC1 scaffolding machinery that includes SLC38A9, Ragulator and vacuolar H^+^-ATPase, leading to Rag GTPase activation and mTORC1 recruitment ^[@R5],\ [@R7],\ [@R10],\ [@R31]^ ([Fig. 8f](#F8){ref-type="fig"}). Notably, OSBP was unique among VAP-interacting proteins in directly controlling mTORC1 activation. The partial decrease in mTORC1 signaling caused by depleting ORP8 and ORP11 likely occurs via indirect mechanisms not connected to lysosomal cholesterol trafficking ^[@R16],\ [@R45],\ [@R51]--[@R53]^

In yeast, intracellular transport of ergosterol has been implicated in TORC1 regulation by nitrogen, as well as its inactivation under stress ^[@R54],\ [@R55]^. Through the transport action of OSBP-VAP, ER-lysosome contacts in metazoan cells emerge as signaling nodes where information about cholesterol availability is integrated and translated into mTORC1-driven growth programs. Because the majority of endo-lysosomes contact the ER over time scales of several minutes, the regulatory action of these junctions on mTORC1 signaling is expected to be pervasive and to couple the pace of cell growth to the levels of intracellular cholesterol ^[@R2],\ [@R3]^

Our results shed light on how NPC1 regulates lysosomal cholesterol levels, a problem with significant implications for metabolic and neurodegeneration research ^[@R14],\ [@R56]^. Upon accepting luminal cholesterol from NPC2, NPC1 may facilitate its insertion into the lysosomal limiting membrane for subsequent export, or directly hand it over to acceptors that remain unidentified ^[@R11]--[@R13],\ [@R57]^. How does cholesterol handling by NPC1 lead to mTORC1 inhibition? Recent evidence indicates that LDL-derived cholesterol is rapidly removed from the lysosome and transported to the plasma membrane in an NPC1-dependent manner ^[@R58]^. Rapid, NPC1-dependent export may prevent cholesterol liberated from LDL from accumulating at the lysosomal surface and interacting with the mTORC1 scaffolding complex ^[@R7]^. Subsequently, OSBP-VAP may return cholesterol to the lysosomal surface across ER-lysosome contacts in a controlled manner. Consistent with this model, exogenously delivered TopFluor-cholesterol requires OSBP to exit the ER and reach the lysosomal limiting membrane.

Alternatively, NPC1 may promote the lateral segregation of lysosomal membrane cholesterol into domains analogous to the ones reported on the yeast vacuole, and which may not be accessible to the mTORC1 scaffolding complex ^[@R59],\ [@R60]^. Ultimately, mTORC1 activity results from the balance between the sterol-transport activities of OSBP-VAP and NPC1. While we could not detect a direct interaction between OSBP and NPC1 in co-IP studies, we did find that NPC1 status affects the interaction between OSBP and VAPA/B. Thus, NPC1 may exert feedback regulation on OSBP, possibly via its cholesterol transport activity. Further studies are required to shed light on the mechanistic basis for this regulation. More broadly, these data support the idea that ER-lysosome contacts are *bona fide* signaling structures, that can modulate the rate of cholesterol transport in response to physiological stimuli. Moreover, given that neither NPC1 nor OSBP are required for acute mTORC1 response to amino acids^[@R7]^ ([Supplementary Fig. 6g](#SD1){ref-type="supplementary-material"}), ER-lysosome contacts are likely dedicated to mTORC1 regulation by cholesterol inputs.

By modulating the cholesterol content of the lysosomal limiting membrane, OSBP has a profound influence on the initiation and execution of autophagy. This was especially evident in cellular models of Niemann-Pick type C, where OSBP inhibition was sufficient to restore autophagic flux, leading to clearance of the canonical autophagic substrate, p62. Previous studies in patient-derived cells have uncovered defects in both autophagosome-lysosome fusion and in the subsequent breakdown of autophagic substrates ^[@R29],\ [@R47],\ [@R48],\ [@R61]^. These defects can be explained, at least in part, by the observed accumulation of cholesterol on the lysosomal limiting membrane ([Fig. 1b](#F1){ref-type="fig"} and [1c](#F1){ref-type="fig"}), which could lead to mis-trafficking of lysosomes and compromise their ability to fuse with other organelles ^[@R24],\ [@R62],\ [@R63]^. In the context of NPC, OSBP inhibition restores autophagic function likely by reducing cholesterol buildup at the lysosomal membrane, which has the dual effect of enhancing autophagy initiation (via mTORC1 inhibition) and, potentially, restoring lysosomal trafficking and fusion with autophagosomes.

The availability of nanomolar OSBP inhibitors, such as OSW-1 ^[@R33]^, suggests that chemical modulation of OSBP could be a promising strategy to correct lysosomal function and to restore proteostasis in Niemann-Pick type C, as well as in diseases driven by excess mTORC1 signaling.

Methods {#S9}
=======

Antibodies and Chemicals {#S10}
------------------------

Antibodies used in this study are listed in [Supplementary Table 3](#SD4){ref-type="supplementary-material"}. LDL (J65039) from Alfa Aesar. Amino acids, lysozyme (62970), cholesterol (C3045), filipin (F9765) and methyl-beta-cyclodextrin ((MCD), C4555), bafilomycin A1 (B1793), U18666A (U3633) from Sigma-Aldrich. TopFluor-cholesterol (810255P) from Avanti Polar Lipids. Torin1 (4247) from Tocris Bioscience. Pierce Protease Inhibitor Tablets (A32965) from Thermo Fisher Scientific. Glutathione Sepharose 4B (17--0756-05) from Pierce. LysoSensor Green DND-189 (L7535) and DMEM (11965) from Life Technologies. Amino acid-free RPMI (R9010--01) from US Biologicals. OSW-1 was a generous gift from Matthew D Shair (Harvard University).

Mammalian cell culture {#S11}
----------------------

Human HEK-293A, HEK-293T, HEK-293T NPC1-null, HEK-293T NPRL3-null, HEK-293T KPTN-null, MEFs *Npc1*^+/+^, and MEFs *Npc1*^−/−^ cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) inactivated fetal bovine serum (Sigma-Aldrich), penicillin (100 U/ml), streptomycin (100 μg/ml) and 2 mM L-glutamine. Human NPC1^WT^ (GM23151) and NPC1^mut^ fibroblasts (GM03123) were obtained from Coriell Cell Repositories in full compliance with the Office for Human Research Protections, Department of Health and Human Services ("DHHS") regulations. The statement of research intent and the signed MTA were submitted and approved by the Coriell Institutional Review Board for use of patient cells in this study. Human fibroblasts were grown in DMEM with 15% fetal bovine serum. All cell lines were maintained at 37 °C and 5% CO~2~. They were free of mycoplasma contamination, and routinely checked using MycoAlert Mycoplasma Detection Kit (Lonza, LT07--318) and Hoechst staining.

Plasmids, viruses and stable cell lines {#S12}
---------------------------------------

The pLKO.1 lentiviral vector (TRC, Broad institute) was used to express the shRNA against the proteins of interest: OSBP, TRCN0000155752 \| ORP8, TRCN0000147289 \| ORP11, TRCN0000161454 \| ORP5, TRCN0000180915 \| VAPA, TRCN0000029130 \| VAPB, TRCN0000151599 \| STARD3, TRCN0000150515 \| LUCIFERASE as non-targeting control, TRCN0000072243. In cases where indicated, a doxycycline-inducible shRNA system via Tet-pLKO-puro (Addgene \#21915) was used to silence OSBP using doxycycline.

For protein expression, cDNA encoding proteins were cloned into the pLJM1 lentiviral vector carrying a FLAG tag or a FLAG tag followed by a GFP marker accordingly. OSBP cDNA was codon optimized and its variants (R108L, F359A/F360A, H522A/H523A, ΔELSK: deletion of 430--433 aa, K736A) were generated via Agilent QuikChange II site-directed mutagenesis. As for organelle-targeted OSBP truncations, the coding sequence of p18 N-terminal 1--39 aa was inserted to the N terminus of OSBP ΔPH cDNA to generate Lyso-ΔPH-OSBP; Golgi-ΔPH was generated by fusing the coding sequence of Giantin C-terminal 3131--3259 aa to the C terminus of ΔPH; Mito-ΔPH was made by inserting the coding sequence of TOM20 1--145 aa to the N terminus of ΔPH; ER-ΔPH was generated by inserting the coding sequence of ORP8 C-terminal transmembrane region 860--887 aa to the C terminus of ΔPH.

GFP-P4M and mCherry-P4M cDNAs were obtained from Gerry Hammond and cloned into pLJM1 vectors. The scSac1 catalytic domain cDNAs (WT and C389S, catalytically inactive) were obtained from Sergio Grinstein, subjected to human codon optimization, and fused into the C terminus of Lyso-FLAG-GFP in pLJM1 background. As for pGEX-KG-D4H\*-mCherry, D4H-mCherry cDNA was obtained from Gregory D. Fairn and inserted into the pGEX-KG vector. The construct was renamed to D4H\*-mCherry as two mutations including Y415A and A463W were introduced to improve the sensitivity of cholesterol binding, in addition to the D434S of the original D4H cDNA. The autophagic flux reporter pMRX-IP-GFP-LC3-RFP-LC3ΔG was from Addgene, \#84572.

All proteins were either acutely knockdown or stably expressed through lentiviral infection. Lentiviruses were produced by co-transfecting HEK293T cells with lentiviral expression/shRNA cassette and packaging plasmids (pMD2.5G, Addgene \#12259 and psPAX2, Addgene \#12260) using the calcium phosphate transfection method. Viral supernatant was collected 24 hours after transfection, centrifuged at 1,000 g for 5 minutes and filtered with 0.45 μm filter. The viruses were further concentrated using Lenti-X Concentrator (Clontech, 631231) according to the manufacturer's instructions. Target cells were plated in 6-well plates with 8 μg/ml polybrene (Millipore, TR-1003-G) and incubated with virus containing media for 24 hours. After removal of viruses, cells were supplemented with fresh media containing 2 μg/ml puromycin (Calbiochem, 540411). Protein expression was confirmed by immunoblotting and fluorescence microscopy.

For generation of ORP1L knockout cells, guide RNA sequence targeting human *OSBPL1A* exon 2 (AATCACTTCATTCCTCGCCA) was cloned into lentiCRISPRv2 vector (Addgene \# \#52961). HEK-293T cells were infected with viral supernatants generated from lentiCRISPRv2 and selected with puromycin for 2 days. Clonal lines were subsequently performed by limiting dilution and validated by immunoblot analysis of ORP1L expression.

Cholesterol starvation/stimulation {#S13}
----------------------------------

HEK-293T cells in culture dishes were rinsed with serum-free media and incubated in 0.5% methyl-beta cyclodextrin (MCD) supplemented with 0.5% lipid-depleted serum (LDS) for 2 hours and, where indicated, stimulated with DMEM supplemented with 0.1% MCD and 0.5% LDS, and 50 μM cholesterol for 2 hours ^[@R7]^. LDS was prepared as described ^[@R64]^

Cell lysis and immunoprecipitation {#S14}
----------------------------------

Cells were rinsed with cold PBS and lysed in lysis buffer (1% Triton X-100, 10 mM β-glycerol phosphate, 10 mM sodium pyrophosphate, 4 mM EDTA, 40 mM HEPES at pH 7.4, and 1 tablet of EDTA-free protease inhibitors per 50 ml). Cell lysates were cleared by centrifugation in a microcentrifuge at 17,000 g for 10 minutes at 4 °C. Cell lysate samples were prepared by addition of 5X sample buffer, heated at 70 °C for 10 minutes, resolved by either 10% or 12% SDS-PAGE gels, and analyzed by immunoblotting.

For FLAG immunoprecipitations, 25 μL of a well-mixed 50% slurry of anti-FLAG M2 Affinity Gel (Sigma, A2220) was added to each lysate (1 mg/ml) and incubated at 4 °C in a shaker for 2 hours. Immunoprecipitates were washed five times, twice with lysis buffer and thrice with lysis buffer with 500 mM NaCl. Immunoprecipitated proteins were denatured by addition of 50 μL of 2X urea sample buffer and heating to 37 °C for 15 minutes, resolved by SDS-PAGE, and analyzed by immunoblotting.

Immunofluorescence {#S15}
------------------

HEK-293T or HEK-293A cells were seeded on fibronectin-coated glass coverslips in 6-well plates (35 mm diameter/well), at 300,000--500,000 cells/well and allowed to attach overnight. On the following day, cells were subjected to sterol depletion and restimulation, where indicated, and fixed in 4% paraformaldehyde (PFA) for 15 minutes at room temperature. The coverslips were rinsed twice with PBS and cells were permeabilized with 0.1% (w/v) saponin in PBS for 10 minutes. After rinsing twice with PBS, the slides were incubated with primary antibodies in 5% normal donkey serum (Jackson ImmunoResearch, 017--000-121) for 1 hour at room temperature, rinsed four times with PBS, and incubated with fluorophore-conjugated secondary antibodies derived from goat or donkey (Life Technologies, diluted 1:400 in 5% normal donkey serum, PBS) for 45 minutes at room temperature in the dark. After washing four times with PBS and one time with deionized water, the coverslips were mounted on glass slides using Fluoromount-G (SouthernBiotech, 0100--01) and imaged on a spinning disk confocal system built upon a Nikon Eclipse Ti microscope with Andor Zyla-4.5 sCMOS camera.

Live-cell imaging of PI4P distribution {#S16}
--------------------------------------

Cells expressing PI4P fluorescent reporter (either GFP-P4M or mCherry-P4M) were seeded on 35-mm glass-bottom dishes (MatTeK, P35GC-1.5--14-C), allowed to attach overnight, and imaged on a spinning disk microscope. Prior to imaging, cells were transferred to imaging buffer containing 125 mM NaCl, 5 mM KCl, 1.3 mM CaCl~2~, 1.2 mM MgCl~2~, 25 mM HEPES, and 5 mM D-glucose with pH adjusted to 7.4 with NaOH.

Co-localization analysis {#S17}
------------------------

For quantification of cells with the phenotype of interest, 20 to 25 non-overlapping whole-field images were randomly acquired throughout the slide of each sample. All the RAW images were exported from the Andor iQ3 Imaging Software version 3.3.1 (Andor Technology, Oxford Instruments). The Fiji Software version 1.51j (ImageJ, NIH) was used to quantify the fluorescence intensity ([https://fiji.sc](https://fiji.sc/)). To determine the co-localization of mTOR, OSBP, or p62 with LAMP2-positive lysosomes, or co-labeling of D4H\*-labeled vesicles with the intracellular filipin deposits, individual channels were segmented to identify *bona fide* vesicles using a binary mask via an intensity thresholding function. Co-localization between the respective channels (mTOR / LAMP2, OSBP / LAMP2, p62 / LAMP2, or D4H\* / filipin) was measured using the *AND* function and plotted as the fraction of LAMP2-positive (or filipin-positive) vesicles that are also positive for mTOR (or OSBP, p62, D4H\*). In cases where indicated, co-localization data was normalized to the reference group for multiple comparisons. In general, ten fields of view per condition except otherwise stated were subjected to thresholding for quantification. The number of cells included for analysis per condition and the number of independent experiments were indicated in the figure legends accordingly.

Lysosome immunoprecipitation {#S18}
----------------------------

Lysosomes carrying Tmem192-mRFP-3xHA were purified as described previously ^[@R7],\ [@R32]^. Confluent HEK293T cells stably expressing Tmem192-mRFP-3xHA in a 15-cm culture dish were scraped in chilled PBS and collected by centrifugation at 300 g for 10 minutes at 4 °C. Cells were re-suspended, lysed using a 23G syringe in KPBS buffer (136 mM KCl, 10 mM KH~2~PO~4~, pH 7.25), and spun at 700 g for 10 minutes at 4 °C. The post nuclear supernatant (PNS) was then incubated with 50 μL of anti-HA magnetic beads, washed in KPBS buffer, for 5 minutes at 4 °C. Lysosome-bound beads were then washed three times in KPBS buffer, re-suspended in 2X urea sample buffer for immunoblotting, or extracted of lipids with methanol and ethyl acetate for lysosomal cholesterol measurement.

Lysosomal cholesterol measurement using mass spectrometry {#S19}
---------------------------------------------------------

The lysosomal samples were extracted from anti-HA magnetic beads with methanol and ethyl acetate with d7-cholesterol (2 μg per sample), and further derivatized with nicotinic acid to improve the mass spectrometric detection sensitivity of cholesterol. Measurement of cholesterol was performed with a Shimadzu 10A HPLC system and a Shimadzu SIL-20AC HT auto-sampler coupled to a Thermo Scientific TSQ Quantum Ultra triple quadrupole mass spectrometer. Data processing was conducted with Xcalibur™ Software version 4.0 (Thermo Fisher Scientific). A quality control (QC) sample was prepared by pooling the aliquots of the study samples and was used to monitor the instrument stability. The QC was injected six times in the beginning to stabilize the instrument and was injected every four study samples to monitor the instrument performance. The data was accepted if the coefficient variance (CV) of cholesterol in QC sample was \< 15%. The data was reported as the peak area ratio of cholesterol to d7-cholesterol.

Whole-cell lipidome analysis {#S20}
----------------------------

HEK-293T cells cultured in 6-well plates were depleted of OSBP by doxycycline-induced shRNA, washed twice with PBS, harvested by scraping, and collected by bench-top centrifugation at 1000 g at 4 °C, and cell pellets were flash frozen and stored at −80 °C until metabolome extractions. Lipid metabolites were extracted in 4 mL of a 2:1:1 mixture of chloroform/methanol/Tris buffer with inclusion of internal standards C12:0 dodecylglycerol (10 nmol) and pentadecanoic acid (10 nmol). Organic and aqueous layers were separated by centrifugation at 1000 g for 5 minutes, and the organic layer was collected. The aqueous layer was acidified (for metabolites such as LPA) by adding 0.1% formic acid, followed by the addition of 2 mL of chloroform. The mixture was vortexed, and the organic layers were combined, dried down under liquid nitrogen, and dissolved in 120 μL of chloroform, of which 10 μL was analyzed by both single-reaction monitoring (SRM)-based LC-MS/MS or untargeted LC-MS. LC separation was achieved with a Luna reverse-phase C5 column (50 mm × 4.6 mm with 5 μm diameter particles, Phenomenex). Mobile phase A was composed of a 95:5 ratio of water/methanol, and mobile phase B consisted of 2-propanol, methanol, and water in a 60:35:5 ratio. Solvent modifiers 0.1% formic acid with 5 mM ammonium formate and 0.1% ammonium hydroxide were used to assist ion formation as well as to improve the LC resolution in both positive and negative ionization modes, respectively. The flow rate for each run started at 0.1 mL/min for 5 minutes, to alleviate backpressure associated with injection of chloroform. The gradient started at 0% B and increased linearly to 100% B over the course of 45 minutes with a flow rate of 0.4 mL/min, followed by an isocratic gradient of 100% B for 17 minutes at 0.5 mL/min before equilibrating for 8 minutes at 0% B with a flow rate of 0.5 mL/min.

Mass spectrometry analysis was performed with an electrospray ionization (ESI) source on an Agilent 6430 QQQ LC-MS/MS. The capillary voltage was set to 3.0 kV, and the fragmentor voltage was set to 100 V. The drying gas temperature was 350 °C, the drying gas flow rate was 10 L/ min, and the nebulizer pressure was 35 psi. Representative metabolites were quantified by SRM of the transition from precursor to product ions at associated collision energies. Data were normalized to the internal standards, and also external standard curves of metabolite classes against the internal standards and levels were expressed as relative metabolite levels compared to controls. For absolute quantification of cellular cholesterol levels as shown in [Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}, serial dilution of free cholesterol, cholesteryl oleate and cholesteryl ester, ranging from 1 mM to 1 nM, was prepared, subjected to 2:1 chloroform:methanol extraction along with appropriate internal standards, and ran through the LC-MS. The ratios of the integrations for cholesterol/C12MAGE, cholesteryl oleate/C12MAGE, choleseteryl ester/C12MAGE were determined respectively and plotted in inverse. A polynomial trend line was fit to the data and the resulting equation was used to calculate the amounts of the lipids at 1 million cells per cell pellet.

Purification of recombinant GST-D4H\*-mCherry {#S21}
---------------------------------------------

GST-fusion D4H\*-mCherry was expressed in BL21 *Escherichia coli* and induced for protein production with 0.4 mM IPTG for 20 hours at 18 °C when the OD~600~ of bacteria growth reached \~ 0.6. Bacteria pellets were suspended in Buffer A (20 mM Tris-Cl, pH 8.0, 0.1 M NaCl, 1 mM DTT) containing protease inhibitor cocktail tablet (Pierce) and incubated with 0.35 mg/ml lysozyme on ice for 30 minutes. The bacterial lysate was sonicated on ice using an ultrasonic processor Q700 (QSONICA Sonicators) with 12 cycles of a 10-second pulse followed by a 10-second break at 50% amplitude output for 4 minutes. The lysate was treated with 0.5% Triton-X-100 and rocked at 4 °C for 15 minutes. The lysate was cleared by centrifugation at 17,000 g at 4 °C for 30 minutes. The pre-equilibrated glutathione-Sepharose 4B beads (GE Healthcare) in Buffer A with 0.1% Triton-X-100 were incubated with clear supernatant for 2 hour at 4 °C. GST-fusion D4H\*-mCherry proteins were eluted from beads with 25 mM L-glutathione solution in 50 mM Tris-Cl, pH 8.8 and 200 mM NaCl. The fractions of the eluate were pooled and filtered using 3K and 30K centrifugal filter units (Amicon Ultra, Millipore) to remove glutathione and concentrate the protein in 50 mM Tris-Cl, pH 8.0, 5 mM DTT. The protein solution was then supplemented with 20% sucrose and frozen in liquid nitrogen. The qualities of the recombinant protein of different batches were validated by Coomassie blue staining.

Labeling of cholesterol with GST-D4H\*-mCherry and filipin {#S22}
----------------------------------------------------------

*In situ* labeling of cholesterol was performed by adopting a protocol as previously described ^[@R16]^. Cells were plated on fibronectin-coated coverslips, subjected to treatment as indicated, fixed with 4% PFA for 10 minutes at the room temperature, and permeabilized in a liquid nitrogen bath for 30 seconds. After blocking with 1% BSA in PBS for 1 hour, the cells were incubated with recombinant GST-D4H\*-mCherry (1:100 dilution, 1% BSA in PBS) for 2 hours. The samples were rinsed twice with PBS, re-fixed with 4% PFA for 10 minutes, incubated with filipin solution (0.5 mg/ml in PBS) for 2 hours, immunostained with LAMP2 or LAMP1, where indicated, and washed four times with PBS. Coverslips were mounted on glass slides using Fluoromount-G and imaged on a spinning disk confocal microscope.

TopFluor-Cholesterol trafficking {#S23}
--------------------------------

HEK-293T cells stably expressing Tmem192-mRFP-3xHA were incubated with DMEM containing 1.5% LDS, treated with DMSO or 20 nM OSW-1 for 2 hours. A total of 20 nmol/ml TopFluor-cholesterol complexed with 0.1 % MCD in DMEM containing 1.5% LDS was loaded to the cells for 10 min on ice. After rinsing with PBS, cells were incubated at 37 °C, chased at the indicated times, fixed with 4% PFA, and imaged on a spinning disk confocal microscope.

Proximity Ligation Assay (PLA) for *in situ* detection of ER-lysosome contacts {#S24}
------------------------------------------------------------------------------

Human NPC1^WT^ and NPC1^mut^ fibroblasts were seeded on fibronectin-coated coverslips, fixed with 4% PFA, and subjected to proximity ligation assay according to manufacturer's protocol (SigmaAldrich, Duolink® In Situ Detection Reagents FarRed, DUO92013). Briefly, after permeabilization with 0.1% saponin, the cells were subjected to blocking, incubation with VAPA and LAMP2 antibodies, either alone or in combination as indicated for 1 hour at room temperature, hybridization with PLA probes, ligation, amplification, and finally Hoechst staining. The number of PLA puncta, indicative of a close apposition between VAPA (ER) and LAMP2 (lysosome), were quantified accordingly as mentioned in the section of co-localization analysis.

Autophagic flux reporter assay {#S25}
------------------------------

*Npc1*^+/+^ and *Npc1*^−/−^ MEF cells expressing GFP-LC3-RFP-LC3ΔG reporter ^[@R49]^ were generated by retrovirus-mediated transduction. After puromycin selection, cells were seeded in fibronectin-coated 96-well plate at 25,000 cells/well and grown overnight. The cells were then treated with either 20 nM OSW-1, 100 nM Bafilomyin A1, or 250 nM Torin1 for 24 hours, respectively, and fixed with 4% PFA in PBS for 15 minutes. The fluorescence intensity of GFP and RFP per well was measured using a microplate reader (SpectraMax i3, Molecular Devices) with excitation/emission at 488/509 nm and 584/607 nm, respectively.

Statistics and Reproducibility {#S26}
------------------------------

Data were expressed as mean ± s.d. where indicated in the figure legends. Statistical analyses were performed using unpaired, two-tailed Student's t-test or one-way analysis of variance (ANOVA) for group comparisons, where indicated, using the GraphPad Prism version 7.0a (GraphPad Software, Inc.). For box plots, the upper and lower edges of the box indicate the first and third quartiles (25^th^ and 75^th^ percentiles) of the data, and the middle line indicates the median, and the whiskers extend to the minimum and maximum. The levels of statistical significance were presented as asterisks and the exact *P* values were indicated in each figure legend along with the statistical tests, respectively. Experiments in [Fig. 8c](#F8){ref-type="fig"}, [Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"} and [6h](#SD1){ref-type="supplementary-material"} were performed once. All other experiments reported here were performed at least two to three times independently and all attempts at replication were successful with similar results.

Data availability {#S27}
-----------------

Mass spectrometry data that support the findings of this study are presented in [Supplementary Table 1](#SD2){ref-type="supplementary-material"} and have been deposited in ProteomeXchange with the primary accession code \[PXD014733\]. Statistics source data for [Figs. 1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"}, [6](#F6){ref-type="fig"}--[8](#F8){ref-type="fig"} and [Supplementary Figs. 1](#SD1){ref-type="supplementary-material"}--[6](#SD1){ref-type="supplementary-material"} are provided in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}. All data supporting the findings of this study are available from the corresponding author on reasonable request.
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![Cholesterol accumulates at the limiting membrane of NPC1-deficient lysosomes in an OSBP-dependent manner.\
**a**, *In situ* labeling assay for detecting lysosomal membrane cholesterol. **b**, Cholesterol is deposited at the lysosomal membrane in human NPC1 patient-derived fibroblasts. Control (NPC1^WT^) and NPC1 (NPC1^mut^) fibroblasts were fixed, breached with LN~2~ pulse, subjected to cholesterol labeling by GST-D4H\*-mCherry and filipin, and stained for LAMP2. Scale bar, 10 μm. **c**, NPC1 deletion via CRISPR/Cas9 genome editing in cells results in cholesterol accumulation at the lysosomal membrane. NPC1-deleted HEK-293T cells expressing FLAG-GFP-Tmem192, either naïve or reconstituted with FLAG-tagged NPC1, were processed for cholesterol labeling. Scale bar, 10 μm. Insets show three examples per genotype. **d**, Proteomic analysis of affinity-purified lysosomes. Lysosomes were immunopurified by anti-FLAG M2 beads (or anti-HA magnetic beads) from HEK-293T cells expressing LAMP1-mRFP-2xFLAG or Tmem192-mRFP-3xHA and analyzed by mass spectrometry. Unique peptide counts for identified ORPs shown here (*n* = 2 independent experiments, 5 biologically independent samples in total). See [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. **e**, Pull-down of lysosomes revealing the lysosomal association of ORPs. Lysosomes were purified by anti-HA beads and immunoblotted for the indicated proteins. **f**, Quantitation of co-localization of D4H\*-mCherry with filipin-labeled cholesterol deposits in NPC1-null cells depleted of ORPs (box plots showing the min, 1^st^ quartile, median, 3^rd^ quartile, and max, 10 fields of view per genotype; *n* represents cell number: shLuc (*n* = 13), shOR8 (*n* = 12), shORP11 (*n* = 12), shOSBP (*n* = 11), shORP5 (*n* = 10), ANOVA with Dunnett's multiple comparison test. \*\*\*\*Adjusted *P* = 0.0001 vs. NPC1^mut^-shLuc). See [Supplementary Fig. 1g](#SD1){ref-type="supplementary-material"}. **g** and **h**, Concomitant depletion of OSBP in NPC1-null cells reduces lysosomal membrane cholesterol levels. Cells were depleted of OSBP via doxycycline-induced shRNA and processed for cholesterol labeling. Scale bar, 10 μm. Insets show three examples per genotype. Quantitation in (**g**) (box plots as in (**f**), 10 fields of view per group; *n* represents cell number: -- Dox (*n* = 64), + Dox (*n* = 72), two-tailed, unpaired t-test. \*\*\*\**P* = 1.16578 × 10^−13^ vs. -- Dox group). Experiments in **b, c** performed three times and in **e**, **g** two times.](nihms-1537600-f0001){#F1}

![OSBP is required for cholesterol-dependent lysosomal recruitment and activation of mTORC1.\
**a**, OSBP inhibition by OSW-1 treatment reduces the lysosomal cholesterol content. HEK-293T cells expressing Tmem192-mRFP-3xHA were treated with DMSO or 20 nM OSW-1 for 8h. Lysosomes were purified and analyzed by mass spectrometry (mean ± s.d., *n* = 4 biologically independent samples per treatment, two-tailed, unpaired t-test. \*\*\*\**P* = 1.61895 × 10^−6^ vs. DMSO). See immunoblots in [Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}. **b**, OSBP is specifically required for lysosomal recruitment of mTORC1 by cholesterol. Cells depleted of OSBP were subjected to cholesterol depletion and restimulation, where indicated, followed by immunofluorescence for endogenous mTOR and LAMP2. Representative images are shown. Scale bar, 10 μm. **c**, Quantitation of co-localization of mTOR with LAMP2-positive lysosomes in cells expressing the indicated shRNAs (mean ± s.d., 10 fields of view per genotype/condition; *n* represents cell number: shLuc -- chol (*n* = 182), shLuc + chol (*n* = 181), shORP8 -- chol (*n* = 104), shORP8 + chol (*n* = 91), shORP11 -- chol (*n* = 157), shORP11 + chol (*n* = 156), shOSBP -- chol (*n* = 176), shOSBP + chol (*n* = 182), shORP5 -- chol (*n* = 160), shORP5 + chol (*n* = 166), ANOVA with Dunnett's multiple comparison test. \*\*\*\*Adjusted *P* = 0.0001 vs. shLuc + chol). See representative images in [Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}. **d**, ORPs affect mTORC1 activation by cholesterol. Cells were sterol-depleted using methyl-beta cyclodextrin (MCD, 0.5% w/v) for 2h and restimulated for 2h with 50 μM cholesterol complexed with 0.1% MCD (MCD:cholesterol). Cell lysates were analyzed for the levels of indicated proteins and for phosphorylation status of S6K1 (T389), 4E-BP1 (S65). Fold changes of protein phosphorylation are indicated. **e**, OSW-1 inhibits sterol-induced mTORC1 signaling in a dose-dependent manner. Cells were subjected to cholesterol starvation and restimulation in the presence of DMSO or OSW-1 at the indicated concentrations and immunoblotted for the indicated proteins. Experiments in **b, d** performed three times and in **a**, **e** two times. See unprocessed blots in [Supplementary Figure 9](#SD1){ref-type="supplementary-material"}. Statistics source data are provided in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}.](nihms-1537600-f0002){#F2}

![OSBP regulates mTORC1 upstream of the Rag GTPases.\
**a**, OSBP depletion abolishes sterol-dependent mTORC1 recruitment to lysosomes without compromising the integrity of mTORC1 scaffolding complex. Quantitation of co-localization of mTOR, p18, and RagC with LAMP2-positive lysosomes (mean ± s.d., 6 fields of view per genotype/condition; *n* represents cell number: mTOR for shLuc -- chol (*n* = 126), shLuc + chol (*n* = 91), shOSBP -- chol (*n* = 115), shOSBP + chol (*n* = 106); p18 for shLuc -- chol (*n* = 105), shLuc + chol (*n* = 101), shOSBP -- chol (*n* = 92), shOSBP + chol (*n* = 89); RagC for shLuc -- chol (*n* = 88), shLuc + chol (*n* = 90), shOSBP -- chol (*n* = 77), shOSBP + chol (*n* = 79), ANOVA with Dunnett's multiple comparison test. \*\*\*\*Adjusted *P* = 0.0001 vs. shLuc + chol). See [Supplementary Fig. 6h](#SD1){ref-type="supplementary-material"}. **b**, OSBP mediates mTORC1 lysosomal recruitment upstream of the Rag GTPases. Control HEK-293T and cells expressing the constitutively active RagB^Q99L^ were depleted of OSBP and evaluated for sterol-dependent lysosomal localization of mTORC1. Scale bar, 10 μm. **c**, Quantitation of co-localization of mTOR with LAMP2-positive lysosomes (mean ± s.d., 10 fields of view per each genotype/condition; *n* represents cell number: CTRL-shLuc -- chol (*n* = 185), CTRL-shLuc + chol (*n* = 146), CTRL-shOSBP -- chol (*n* = 154), CTRL-shOSBP + chol (*n* = 164); RagB^Q99L^-shLuc -- chol (*n* = 142), RagB^Q99L^-shLuc + chol (*n* = 148), RagB^Q99L^-shOSBP -- chol (*n* = 128), RagB^Q99L^-shOSBP + chol (*n* = 143), ANOVA with Dunnett's multiple comparison test. \*\*\*\*Adjusted *P* = 0.0001 as indicated). **d**, OSBP activates mTORC1 signaling via the Rag GTPases. Cells were starved of cholesterol, refed where indicated, and analyzed for mTORC1 signaling. **e** and **f**, Loss of GATOR1 or KICSTOR largely rescues the effects of OSBP depletion on mTORC1 signaling. NPRL3-deleted (**e**) or KPTN-deleted (**f**) HEK-293T cells were analyzed for sterol-induced mTORC1 signaling. Fold changes of protein phosphorylation are shown in **d**, **e** and **f**. Experiments in **d**, **e** and **f** repeated independently two times. See unprocessed blots in [Supplementary Figure 9](#SD1){ref-type="supplementary-material"}. Statistics source data are provided in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}.](nihms-1537600-f0003){#F3}

![Both the lipid-transporting and lysosome-targeting functions of OSBP are required for mTORC1 activation by cholesterol.\
**a**, Domain organization of OSBP and related functions. **b**, The membrane tethering and lipid transfer functions of OSBP are required for lysosomal recruitment of mTORC1. OSBP-depleted cells and cells that were re-engineered as indicated were subjected to cholesterol starvation and restimulation, followed by immunofluorescence for endogenous mTOR and LAMP2. Scale bar, 10 μm. **c**, Quantitation of co-localization of mTOR with LAMP2-positive lysosomes in cells reconstituted with different truncations as indicated (mean ± s.d., 10 fields of view per each genotype/condition; *n* represents cell number: shOSBP -- chol (*n* = 173), shOSBP + chol (*n* = 170), rescued WT -- chol (*n* = 185), rescued WT + chol (*n* = 154), rescued ΔN -- chol (*n* = 179), rescued ΔN + chol (*n* = 131), rescued ΔPH -- chol (*n* = 169), rescued ΔPH + chol (*n* = 168), rescued PH-FFAT -- chol (*n* = 188), rescued PH-FFAT + chol (*n* = 179), rescued ORD -- chol (*n* = 185), rescued ORD + chol (*n* = 168), ANOVA with Dunnett's multiple comparison test. \*\*\*\*Adjusted *P* = 0.0001 vs. rescued WT + chol). **d**, Linking OSBP to the lysosome but not to other organelles restores mTORC1 activation by cholesterol. Cells were depleted of OSBP and reconstituted with PH domain-deleted isoforms that carry organelle-targeting sequences, subjected to cholesterol starvation and restimulation. Cell lysates were analyzed for the indicated proteins and phospho-proteins. **e**, The lipid transfer activity of lysosome-targeted OSBP is essential for mTORC1 activation. Cells were depleted of OSBP and reconstituted with the indicated lyso-OSBP constructs, subjected to cholesterol starvation and restimulation. Cell lysates were analyzed for the indicated proteins and phospho-proteins. Experiments in **d** and **e** repeated independently two times. See unprocessed blots in [Supplementary Figure 9](#SD1){ref-type="supplementary-material"}. Statistics source data are provided in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}.](nihms-1537600-f0004){#F4}

![Excess lysosomal PI4P upon OSBP inhibition does not cause mTORC1 inhibition.\
**a**, Depletion of OSBP results in accumulation of PI4P at the lysosomes. HEK-293A cells stably expressing the PI4P-specific probe, GFP-P4M, along with LAMP1-mRFP were depleted of OSBP via doxycycline-induced shRNA. Cells were plated on glass-bottom dishes, allowed to attach overnight and imaged live on a spinning disk confocal microscope. Representative microscopic images are shown. Scale bar, 10 μm. **b**, Confirmation of lysosomal localization of the lysosome-targeted Sac1 catalytic domain truncations in HEK-293A cells. (*left*) Schematic diagram showing Sac1 catalytic domain is targeted to the lysosome to hydrolyze its target PI4P. (*right*) Representative microscopic images are shown. Scale bar, 10 μm. **c**, Ectopic expression of a lysosome-targeted Sac1 catalytic domain eliminates excess lysosomal PI4P in OSBP-depleted cells. HEK-293T cells co-expressing mCherry-P4M and either catalytically active (WT) or inactive (CS) forms of lyso-Sac1 were depleted of OSBP and subjected to live-cell imaging. Representative confocal microscopic images are shown. Scale bar, 10 μm. **d**, Lysosomal PI4P buildup caused by OSBP depletion is not responsible for mTORC1 inhibition. Control cells and cells expressing catalytically active and inactive lyso-Sac1 were depleted of OSBP, followed by cholesterol starvation/restimulation, lysis and immunoblotting for the indicated proteins and phospho-proteins. See unprocessed blots in [Supplementary Figure 9](#SD1){ref-type="supplementary-material"}. Experiments in **a**--**d** repeated independently two times.](nihms-1537600-f0005){#F5}

![VAPA and VAPB, the ER anchors for OSBP, are essential for cholesterol-dependent mTORC1 activation.\
**a**, VAPA/B depletion abolishes the lysosomal recruitment of mTORC1 by cholesterol. HEK-293T cells were depleted for VAPA and VAPB via shRNA and evaluated for mTOR lysosomal localization. Scale bar, 10 μm. **b**, Quantitation of co-localization between mTOR and LAMP2-positive lysosomes in control cells and cells depleted of VAPA and B (mean ± s.d., 10 fields of view per genotype/condition; *n* represents cell number: shLuc -- chol (*n* = 124), shLuc + chol (*n* = 74), shVAPA/VAPB -- chol (*n* = 178), shVAPA/VAPB + chol (*n* = 163), ANOVA with Dunnett's multiple comparison test. \*\*\*\**P* = 0.0001 vs. shLuc + chol). **c**, VAPA and VAPB are necessary for cholesterol-dependent mTORC1 activation. HEK-293T cells were depleted of VAPA and VAPB, either alone or in combination, and evaluated for sterol-induced mTORC1 signaling via immunoblotting. **d** and **e**, STARD3 and ORP1L are not required for cholesterol-dependent mTORC1 signaling. Cells depleted of STARD3 or OSBP via shRNA (**d**) and ORP1L knockout cells (**e**) were assayed for sterol-induced mTORC1 activation via immunoblotting. **f**, Depletion of STARD3 or ORP1L has no effects on both peripheral and internal pools of lysosomal cholesterol in NPC1-deficient cells. Human NPC1 patient-derived fibroblasts depleted of STARD3 or OSBP via shRNA or deleted of ORP1L via CRISPR/Cas9 genome editing were subjected to cholesterol labeling by GST-D4H\*-mCherry and filipin, and stained for endogenous LAMP2. Scale bar, 10 μm. **g**, Quantitation of co-localization of D4H\*-mCherry with filipin-labeled cholesterol deposits in NPC1-null cells that were silenced of STARD3, OSBP, and ORP1L, respectively (box plots showing the min, 1^st^ quartile, median, 3^rd^ quartile, and max, 10 fields of view per genotype; *n* represents cell number: shLuc (*n* = 12), shSTARD3 (*n* = 10), shOSBP (*n* = 10), sgORP1L (*n* = 11), ANOVA with Dunnett's multiple comparison test. \*\*\*\*Adjusted *P* = 0.0001 vs. NPC1^mut^-shLuc). Experiments in **c**--**e** performed independently two times with similar results. See unprocessed blots in [Supplementary Figure 9](#SD1){ref-type="supplementary-material"}. Statistics source data are provided in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}.](nihms-1537600-f0006){#F6}

![OSBP inhibition abrogates aberrant mTORC1 signaling in NPC1-deficient cells.\
**a**, (*left*) Increased ER-lysosome contacts in NPC1 fibroblasts. Cells were fixed, permeabilized, labelled with VAPA or LAMP2 antibodies, or in combination as indicated, and subjected to proximity ligation assay (PLA). Scale bar, 10 μm. (*right*) Quantitation of PLA signals (box plots showing the min, 1^st^ quartile, median, 3^rd^ quartile, and max, 60 fields of view per group; *n* represents cell number: NPC1^WT^ (*n* = 60), NPC1^mut^ (*n* = 60), two-tailed, unpaired t-test. \*\*\*\**P* = 2.02047 × 10^−19^ vs. NPC1^WT^). **b**, Cholesterol regulates OSBP-VAP interaction in an NPC1-dependent manner. Control and NPC1-null cells expressing the FLAG-GFP-Tmem192, FLAG-GFP-OSBP-WT, and FLAG-GFP-OSBP-FF\>AA, respectively, were starved and refed with cholesterol, lysed and processed for FLAG immunoprecipitation (IP). Both IP and input samples were analyzed by SDS-PAGE and immunoblotting for the indicated proteins. Experiments repeated two times with similar results. **c**, Depletion of OSBP abolishes constitutive mTORC1 signaling in NPC1-null cells. NPC1-deleted HEK-293T cells, either naïve or reconstituted with stably expressed FLAG-tagged NPC1, were depleted of OSBP and analyzed for sterol-induced mTORC1 signaling via immunoblotting. Experiments repeated two times. **d** and **e**, OSBP depletion abrogates constitutive mTORC1 lysosomal localization in NPC1-null cells. NPC1-deleted HEK-293T cells, either naïve or reconstituted with stably expressed FLAG-tagged NPC1, were depleted of OSBP and evaluated for sterol-dependent mTORC1 lysosomal localization. Scale bar, 10 μm. Quantitation in (**e**) (mean ± s.d., 10 fields of view per each genotype/condition; *n* represents cell number: sgNPC1^res.WT^-shLuc -- chol (*n* = 166), sgNPC1^res.WT^-shLuc + chol (*n* = 110), sgNPC1^res.WT^-shOSBP -- chol (*n* = 181), sgNPC1^res.WT^-shOSBP + chol (*n* = 132), sgNPC1-shLuc -- chol (*n* = 127), sgNPC1-shLuc + chol (*n* = 142), sgNPC1-shOSBP -- chol (*n* = 147), sgNPC1-shOSBP + chol (*n* = 131), ANOVA with Dunnett's multiple comparison test. \*\*\*\*Adjusted *P* = 0.0001 as indicated). See unprocessed blots in [Supplementary Figure 9](#SD1){ref-type="supplementary-material"}. Statistics source data are provided in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}.](nihms-1537600-f0007){#F7}

![OSBP inhibition restores autophagic function in NPC1-deficient cells.\
**a**, OSW-1 increases autophagic flux in both *Npc1*^+/+^ and *Npc1*^−/−^ MEFs expressing the GFP-LC3-RFP-LC3ΔG reporter. Normalized GFP/RFP fluorescence ratio expressed as fold change over DMSO-treated *Npc1*^+/+^ cells (mean ± s.d., *n* represents number of biologically independent samples: *Npc1*^+/+^ DMSO (*n* = 7), *Npc1*^+/+^ OSW-1 (*n* = 7), *Npc1*^+/+^ BafA1 (*n* = 7), *Npc1*^+/+^ Torin1 (*n* = 7), *Npc1*^−/−^ DMSO (*n* = 6), *Npc1*^−/−^ OSW-1 (*n* = 6), *Npc1*^−/−^ BafA1 (*n* = 6), *Npc1*^−/−^ Torin1 (*n* = 6), ANOVA with Dunnett's multiple comparison test. \*\*\*\*Adjusted *P* = 0.0001 as indicated). **b**, OSW-1 treatment abolishes p62/SQSTM1 accumulation in NPC1 fibroblasts. Cells were subjected to the indicted treatments and immunoblotted for p62 and LC3B. Experiments repeated two times. **c**, OSBP depletion reduces p62 accumulation in human NPC1 patient-derived cells. Cells were depleted of OSBP and analyzed by immunoblotting (*n* = 3 biologically independent samples per genotype). Fold changes of LC3B-II to actin in **b** and **c** are indicated. Experiment performed once. **d** and **e**, p62 clearance by OSW-1 in NPC1 fibroblasts. Cells were subjected to treatments for 8h, and stained for p62 and LAMP2. Scale bar, 10 μm. Quantitation in (**e**) (mean ± s.d., 10 fields of view per each genotype/treatment; *n* represents cell number: NPC1^WT^ DMSO (*n* = 14), NPC1^mut^ DMSO (*n* = 10), NPC1^mut^ OSW-1 (*n* = 11), NPC1^mut^ Torin1 (*n* = 11), NPC1^mut^ BafA1 (*n* = 11), NPC1^mut^ BafA1 + OSW-1 (*n* = 12), ANOVA with Dunnett's multiple comparison test. \*\*\*\*Adjusted *P* = 0.0001 vs. DMSO-treated NPC1^mut^ cells). Statistics source data are provided in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}. **f**, Across ER-lysosome contacts, OSBP-VAP generates a peripheral pool of lysosomal cholesterol that recruits and activates mTORC1 via the Rag GTPases. Conversely, NPC1 suppresses mTORC1 by limiting the levels of peripheral cholesterol. Thus, the steady-state levels of mTORC1 activation are balanced by the opposite transport route of cholesterol. In cells lacking NPC1, cholesterol accumulates both in the lysosomal lumen and, via unopposed ER-to-lysosome transport by OSBP, on the lysosomal membrane. In turn, excess lysosomal membrane cholesterol drives constitutively elevated mTORC1 signaling and inhibits autophagy.](nihms-1537600-f0008){#F8}
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